Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Cindy Hsin-Ti Lin,Muhammad Junaid Tariq,Fauzia Ullah,Aishwarya Sannareddy,Farhan Khalid,Hasan Abbas,Abbas Bader,Christy Samaras,Jason Valent,Jack Khouri,Faiz Anwer,Shahzad Raza,Danai Dima
DOI: https://doi.org/10.3390/ijms25116192
IF: 5.6
2024-06-04
International Journal of Molecular Sciences
Abstract:Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, continued research of new targets in MM is crucial to circumvent cumulative drug resistance, overcome treatment-limiting toxicities, and improve outcomes in this incurable disease. This article provides a comprehensive overview of the landscape of novel treatments and emerging therapies for MM grouped by molecular target. Molecular targets outlined include BCMA, GPRC5D, FcRH5, CD38, SLAMF7, BCL-2, kinesin spindle protein, protein disulfide isomerase 1, peptidylprolyl isomerase A, Sec61 translocon, and cyclin-dependent kinase 6. Immunomodulatory drugs, NK cell therapy, and proteolysis-targeting chimera are described as well.
biochemistry & molecular biology,chemistry, multidisciplinary